Document Detail

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.
MedLine Citation:
PMID:  16636248     Owner:  NLM     Status:  MEDLINE    
Patients with recurrent gliomas (n = 14) were treated with bevacizumab and carboplatin, cpt-11, or etoposide. Follow-up MRI scans were obtained 2 to 6 weeks after initiation of treatment. Contrast-enhancing tumor shrank in 7 patients, with reductions evident in as little as 2 weeks after initiation of therapy. Treatment seemed more effective for heterogeneously enhancing tumor compared with solidly enhancing tumor.
W B Pope; A Lai; P Nghiemphu; P Mischel; T F Cloughesy
Related Documents :
16110498 - Etoposide, vincristine, and cyclosporin a with standard-dose radiation therapy in newly...
25418188 - Toxic epidermal necrolysis related to ap (pemetrexed plus cisplatin) and gefitinib comb...
11745268 - Long-term stabilization in patients with malignant glioma after treatment with liposoma...
25479078 - Discordance rate of her2 status in primary gastric carcinomas and synchronous lymph nod...
16458038 - Good tumor control and survivals of squamous cell carcinoma of buccal mucosa treated wi...
20682108 - Intra-arterial chemotherapy with carboplatin (cbdca) and vepesid (vp16) in primary mali...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Neurology     Volume:  66     ISSN:  1526-632X     ISO Abbreviation:  Neurology     Publication Date:  2006 Apr 
Date Detail:
Created Date:  2006-04-25     Completed Date:  2006-06-05     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  0401060     Medline TA:  Neurology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1258-60     Citation Subset:  AIM; IM    
Department of Radiological Sciences, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Camptothecin / analogs & derivatives,  therapeutic use
Carboplatin / therapeutic use
Drug Therapy, Combination
Etoposide / therapeutic use
Glioma / drug therapy,  pathology*,  therapy*
Magnetic Resonance Imaging
Middle Aged
Neoplasm Recurrence, Local / drug therapy,  therapy
Vascular Endothelial Growth Factor A / antagonists & inhibitors,  immunology
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V/bevacizumab; 33419-42-0/Etoposide; 41575-94-4/Carboplatin; 7673326042/irinotecan; 7689-03-4/Camptothecin
Comment In:
Neurology. 2006 Dec 12;67(11):2089; author reply 2089   [PMID:  17159134 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Monocyte chemoattractant protein-1 correlates with subcortical brain injury in HIV infection.
Next Document:  Nonconvulsive status epilepticus in metastatic CNS disease.